• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

退伍军人人群中,肝癌治疗模式和生存状况在不同地理区域的变化。

Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population.

机构信息

Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Department of Population and Clinical Science, University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

Ann Surg Oncol. 2022 Dec;29(13):8413-8420. doi: 10.1245/s10434-022-12390-7. Epub 2022 Aug 26.

DOI:10.1245/s10434-022-12390-7
PMID:36018517
Abstract

BACKGROUND

Veteran populations have five times the incidence of hepatocellular carcinoma (HCC) compared with the general population. The incidence of HCC has increased in the Veteran's Affairs Health System (VAHS), primarily due to the increased prevalence of cirrhosis. This study aimed to characterize differences in treatment patterns and overall survival rates across the five VAHS geographic regions.

METHODS

Using the VA Corporate Data Warehouse, the authors built a comprehensive national dataset of Veteran patients with HCC diagnosed between 2001 and 2015 to compare patients across VAHS regions. A multivariable Cox proportional hazards model was used to identify factors associated with 5-year all-cause mortality. Kaplan-Meier curves were used to visualize the patient survival function, and the log-rank test was applied to test statistical significance.

RESULTS

This retrospective study analyzed 13,434 patients. The West region had the highest rate of overall treatment receipt (63.6%), and the Southwest had the lowest rate (52.9%). After adjustment for demographic, clinicopathologic, treatment, and hospital factors, treatment in a non-West region continued to be significantly associated with a 10% to 13% increased risk of 5-year mortality (Midwest: hazard ratio [HR], 1.11; 95% confidence interval [CI], 1.03-1.17; Northeast: HR, 1.10; 95% CI, 1.03-1.17; Southeast: HR, 1.13; 95% CI, 1.06-1.21; Southwest: HR, 1.11; 95% CI, 1.03-1.19) (p < 0.01).

CONCLUSIONS

Treatment patterns and overall survival rates of HCC patients differ significantly across VAHS geographic regions. Targeted interventions to increase the rate of treatment in the non-West regions are needed to improve survival of HCC Veterans and provide uniformly high-quality care across VAHS facilities.

摘要

背景

与普通人群相比,退伍军人的肝细胞癌(HCC)发病率是其五倍。由于肝硬化的发病率增加,退伍军人事务部医疗保健系统(VAHS)中的 HCC 发病率有所上升。本研究旨在描述 VAHS 五个地理区域之间治疗模式和总生存率的差异。

方法

作者利用 VA 公司数据仓库,构建了一个包含 2001 年至 2015 年间确诊 HCC 的退伍军人患者的全国性综合数据集,以比较 VAHS 地区的患者。采用多变量 Cox 比例风险模型来确定与 5 年全因死亡率相关的因素。Kaplan-Meier 曲线用于可视化患者的生存函数,对数秩检验用于检验统计学意义。

结果

这项回顾性研究共分析了 13434 名患者。西部地区的总体治疗率最高(63.6%),而西南部地区的治疗率最低(52.9%)。在调整人口统计学、临床病理、治疗和医院因素后,在非西部地区进行治疗仍然与 5 年死亡率增加 10%至 13%显著相关(中西部:风险比 [HR],1.11;95%置信区间 [CI],1.03-1.17;东北部:HR,1.10;95% CI,1.03-1.17;东南部:HR,1.13;95% CI,1.06-1.21;西南部:HR,1.11;95% CI,1.03-1.19)(p < 0.01)。

结论

VAHS 地理区域之间 HCC 患者的治疗模式和总体生存率存在显著差异。需要采取有针对性的干预措施来提高非西部地区的治疗率,以提高 HCC 退伍军人的生存率,并在 VAHS 设施中提供统一的高质量护理。

相似文献

1
Variation of Hepatocellular Carcinoma Treatment Patterns and Survival Across Geographic Regions in a Veteran Population.退伍军人人群中,肝癌治疗模式和生存状况在不同地理区域的变化。
Ann Surg Oncol. 2022 Dec;29(13):8413-8420. doi: 10.1245/s10434-022-12390-7. Epub 2022 Aug 26.
2
Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population.退伍军人人群中早期肝细胞癌治疗利用的趋势和差异。
Ann Surg Oncol. 2022 Sep;29(9):5488-5497. doi: 10.1245/s10434-022-11897-3. Epub 2022 May 22.
3
Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.医疗服务提供者专业与多学科护理与肝细胞癌治疗及死亡率的关联
Gastroenterology. 2017 Jun;152(8):1954-1964. doi: 10.1053/j.gastro.2017.02.040. Epub 2017 Mar 7.
4
Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States.美国肝硬化退伍军人肝细胞癌治疗相关的医疗费用。
Clin Gastroenterol Hepatol. 2018 Jan;16(1):106-114.e5. doi: 10.1016/j.cgh.2017.07.024. Epub 2017 Jul 26.
5
Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.酒精性或病毒性丙型肝硬化患者肝细胞癌的危险因素。
Clin Gastroenterol Hepatol. 2006 Aug;4(8):1062-8. doi: 10.1016/j.cgh.2006.05.013. Epub 2006 Jul 14.
6
Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project.2021 年肝细胞癌的诊断与管理:一项国家退伍军人事务部质量改进项目。
Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi: 10.1016/j.cgh.2023.07.002. Epub 2023 Jul 15.
7
The road to pandemic recovery: Tracking COVID-19's impact on cirrhosis care and outcomes among 111,558 Veterans.大流行后的恢复之路:追踪新冠病毒对111,558名退伍军人肝硬化护理及预后的影响
Hepatology. 2023 Jun 1;77(6):2016-2029. doi: 10.1097/HEP.0000000000000306. Epub 2023 Jan 30.
8
Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.256 例肝细胞癌的流行病学、临床治疗模式和预后。
World J Gastroenterol. 2013 Jun 7;19(21):3207-16. doi: 10.3748/wjg.v19.i21.3207.
9
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.美国丙型肝炎病毒感染者肝癌监测的利用。
Ann Intern Med. 2011 Jan 18;154(2):85-93. doi: 10.7326/0003-4819-154-2-201101180-00006.
10
Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands.肝硬化肝脏与非肝硬化肝脏中的肝细胞癌:来自荷兰一个大型队列的结果。
Eur J Gastroenterol Hepatol. 2016 Mar;28(3):352-9. doi: 10.1097/MEG.0000000000000527.

引用本文的文献

1
Quality of care in hepatocellular carcinoma-A critical review.肝细胞癌的医疗质量——一项批判性综述
Hepatol Commun. 2024 Dec 11;9(1). doi: 10.1097/HC9.0000000000000595. eCollection 2025 Jan 1.
2
Improving the Accuracy and Precision of Disease Identification When Utilizing Ehr Data for Research: the Case for Hepatocellular Carcinoma.利用电子健康记录(EHR)数据进行研究时提高疾病识别的准确性和精确性:以肝细胞癌为例
Res Sq. 2024 Oct 18:rs.3.rs-4993106. doi: 10.21203/rs.3.rs-4993106/v1.
3
From Inflammation to Oncogenesis: Tracing Serum DCLK1 and miRNA Signatures in Chronic Liver Diseases.

本文引用的文献

1
Trends and Disparities in Treatment Utilization for Early-Stage Hepatocellular Carcinoma in the Veteran Population.退伍军人人群中早期肝细胞癌治疗利用的趋势和差异。
Ann Surg Oncol. 2022 Sep;29(9):5488-5497. doi: 10.1245/s10434-022-11897-3. Epub 2022 May 22.
2
Multidisciplinary Teams Improve Gastric Cancer Treatment Efficiency at a Large Safety Net Hospital.多学科团队提高大型医保定点医院胃癌治疗效率。
Ann Surg Oncol. 2020 Mar;27(3):645-650. doi: 10.1245/s10434-019-08037-9. Epub 2019 Nov 1.
3
Liver transplantation for hepatocellular carcinoma: Where do we stand?
从炎症到肿瘤发生:在慢性肝脏疾病中追踪血清 DCLK1 和 miRNA 特征。
Int J Mol Sci. 2024 Jun 12;25(12):6481. doi: 10.3390/ijms25126481.
4
Different Patterns of Care and Survival Outcomes in Transplant-Centre Managed Patients with Early-Stage HCC: Real-World Data from an Australian Multi-Centre Cohort Study.移植中心管理的早期肝癌患者的不同护理模式和生存结果:来自澳大利亚多中心队列研究的真实世界数据。
Cancers (Basel). 2024 May 22;16(11):1966. doi: 10.3390/cancers16111966.
5
Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project.2021 年肝细胞癌的诊断与管理:一项国家退伍军人事务部质量改进项目。
Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi: 10.1016/j.cgh.2023.07.002. Epub 2023 Jul 15.
肝移植治疗肝细胞癌:我们处于什么位置?
World J Gastroenterol. 2019 Jun 7;25(21):2591-2602. doi: 10.3748/wjg.v25.i21.2591.
4
Comparing Quality of Care in Veterans Affairs and Non-Veterans Affairs Settings.比较退伍军人事务部和非退伍军人事务部环境中的医疗保健质量。
J Gen Intern Med. 2018 Oct;33(10):1631-1638. doi: 10.1007/s11606-018-4433-7. Epub 2018 Apr 25.
5
Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality.医疗服务提供者专业与多学科护理与肝细胞癌治疗及死亡率的关联
Gastroenterology. 2017 Jun;152(8):1954-1964. doi: 10.1053/j.gastro.2017.02.040. Epub 2017 Mar 7.
6
Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.2001-2013 年美国退伍军人中潜在肝脏疾病导致的肝硬化和肝细胞癌负担趋势。
Gastroenterology. 2015 Nov;149(6):1471-1482.e5; quiz e17-8. doi: 10.1053/j.gastro.2015.07.056. Epub 2015 Aug 5.
7
Establishment of a Regional Virtual Tumor Board Program to Improve the Process of Care for Patients With Hepatocellular Carcinoma.建立区域虚拟肿瘤委员会项目以改善肝细胞癌患者的治疗流程。
J Oncol Pract. 2015 Jan;11(1):e66-74. doi: 10.1200/JOP.2014.000679. Epub 2014 Dec 2.
8
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.预计 2030 年美国癌症发病与死亡人数:甲状腺癌、肝癌和胰腺癌带来的意外负担。
Cancer Res. 2014 Jun 1;74(11):2913-21. doi: 10.1158/0008-5472.CAN-14-0155.
9
Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome.建立多学科肝细胞癌诊所与改善临床结局相关。
Ann Surg Oncol. 2014 Apr;21(4):1287-95. doi: 10.1245/s10434-013-3413-8. Epub 2013 Dec 7.
10
Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study.肝细胞癌患者的转诊模式和治疗选择:一项基于美国人群的研究。
J Am Coll Surg. 2013 Nov;217(5):896-906. doi: 10.1016/j.jamcollsurg.2013.07.007. Epub 2013 Sep 13.